Synopsis-
- Ichnos Sciences, Glenmark’s drug discovery subsidiary based in the US, on Tuesday said it has entered into an exclusive agreement with Spanish drugmaker Almirall to out-license its novel monoclonal antibody therapy ISB 880 used in treatment of autoimmune diseases.
- Under the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
- Within the terms of the agreement, Almirall will assume full cost and responsibility for the global development and commercialization of the compound for all autoimmune disease indications. Ichnos will receive an upfront payment of €20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.
- ISB 880 is a first-in-class fully human, high affinity monoclonal antibody that targets human IL-1RAP. Blockade of IL-1RAP simultaneously abrogates multiple disease drivers among the IL-1 family of proinflammatory cytokine receptors, including IL-1R, IL-33R, and IL-36R, differentiating ISB 880 from single cytokine blockade therapies.
Ichnos Sciences, ‘s drug discovery subsidiary primarily based within the US, on Tuesday mentioned it has entered into an unique settlement with Spanish drugmaker Almirall to out-license its novel monoclonal antibody remedy ISB 880 utilized in remedy of autoimmune diseases.
Under the settlement, Almirall is granted international rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies appearing on the IL-1RAP pathway for oncology indications.
Within the phrases of the settlement, Almirall will assume full price and accountability for the worldwide improvement and commercialization of the compound for all autoimmune illness indications.
Ichnos will obtain an upfront fee of 20.8 million euros in addition to extra improvement and business milestone funds and tiered royalties primarily based upon future international gross sales.
Glenmark has demerged its drug discovery and improvement operations right into a separate subsidiary known as Ichnos Sciences primarily based in New York City, with the intent of deleveraging its drug pipeline.
Glenmark’s arm Ichnos Sciences enters pact with Almirall Agreement for First-IN-Class IL-1RAP Antagonist Monoclonal Antibody.
Ichnos mentioned the investigational new drug (IND) enabling work has been performed and filings with regulatory authorities are beneath improvement to start human trials.
Autoimmune diseases akin to psoriasis, rheumatoid arthritis, a number of sclerosis, amongst others, are brought on by the immune system mistakenly attacking the physique.
ISB 880 is a first-in-class absolutely human, excessive affinity monoclonal antibody that targets human IL-1RAP. Blockade of IL-1RAP concurrently abrogates a number of illness drivers among the many IL-1 household of proinflammatory cytokine receptors, together with IL1R, IL-33R, and IL-36R, differentiating ISB 880 from single cytokine blockade therapies.
These cytokines have been implicated in quite a few autoimmune situations, opening alternatives for ISB 880 to be positioned throughout broad illness indications.
“ISB 880 anti IL-1RAP antagonist illustrates Ichnos’ core capabilities in biologics discovery and manufacturing, as well as its strategy to advance a pipeline with potential first- or best-in-class assets. Almirall’s excellent team is well positioned to take ISB 880 through testing and development with the goal of delivering this potential new treatment to patients,” mentioned Cyril Konto, president and CEO of Ichnos.
“Given its novel mechanism of action, we believe that ISB 880 has great potential to treat underserved patients across a range of autoimmune dermatological diseases,” mentioned Karl Ziegelbauer, chief scientific officer of Almirall.
“We look forward to beginning to work on ISB 880 and based on the significant data generated by Ichnos we plan to initiate the first-in-human study in the first half of 2022,” Ziegelbauer mentioned.
About Ichnos Sciences Inc.
A fully integrated, global biotech with the spirit of a start-up, Ichnos is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology and autoimmune diseases. The company, with headquarters in New York, N.Y., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and to treat patients holistically. With its patented BEAT® technology platform1, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.
Ichnos continues to advance its pipeline of multispecific antibodies in oncology, with the lead asset, ISB 1342, a CD38 x CD3 bispecific antibody, in Phase 1, and ISB 1442, a CD38 x CD47 2+1 biparatopic bispecific antibody, in IND-enabling studies. Both molecules are being investigated as potential treatments for patients with relapsed/refractory multiple myeloma and other CD38 expressing hematological malignancies. Additional assets from the BEAT® platform may be viewed on the pipeline page of the Ichnos website.
About Almirall
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.
In 2016, it generated total revenue of 859.3 million € and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and United States.
In 2000 the FDA approved anti-migraine agent almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008) and Nordic Countries (2010).
In 2005 the business acquired the commercial rights for Sativex in Europe for the treatment of spasticity associated to multiple sclerosis. In 2006, the company opened its new R&D Centre based in Sant Feliu de Llobregat as well as the acquisition of the Centre of Excellence for Inhalation Technology.In 2007 the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from Shire plc.
In 2011 Almirall launched Actikerall prescribed for the local treatment of actinic keratosis.
In 2016 Almirall acquired ThermiGen LLC.
In January 2020, the company announced it would acquire Bioniz Therapeutic.
The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.
For more information, visit IchnosSciences.com and Almirall.com.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)
